Thousand Oaks biotech giant Amgen details plans for cash
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Fienup: Tax reform improves economic outlook for U.S.
By Matthew Fienup In January 2017, the California Lutheran University Center for Economic Research and Forecasting team made a bold proclamation about the outlook under the new presidential administration: “We assume that Donald Trump will not succeed in changing many of the policies that are primary drivers of the country’s poor economic performance.” As forecasters, Read More →
Higher product sales help Amgen beat analyst expectations for first quarter
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen clinical trial shows promising results for migraine drug Aimovig
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen building plant in Rhode Island
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
European Union approves Amgen’s Xgeva to treat multiple myeloma
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen gets FDA approval for Blincyto
Shares for Amgen ticked up 50 cents after the company announced March 29 that its cancer drug Blincyto had received U.S. Food and Drug Administration approval to treat patients in their first or second remission. The decision makes Blincyto the first therapy to be approved to treat patients with minimal residual disease, or MRD, the Read More →
